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The expression of interleukin-17 in cutaneous lesions of lupus erythematosus in pediatric-onset systemic lupus erythematosus
Editor, Systemic lupus erythematosus (SLE) is the most common connective tissue disorder occurring in children. T H -17 cells and activated interleukin-23 (IL-23)/IL-17 axis play a key role in the pathogenesis of SLE [1] and possibly in SLE-related skin lesions, but studies related to the latter are scarce. [2, 3] A pilot study was conducted to look for the expression of IL-17 in skin biopsies of specific and nonspecific lesions in pediatric-onset SLE (pSLE). The relationship, if any, between the expression of IL-17 and disease activity (Systemic Lupus Erythematosus Disease Activity Index-2000 [SLEDAI-2K]) score was also looked at. A hospital-based, cross-sectional study was done in the dermatology department with the approval of the Institutional Review Board and Ethics Committee. Representative skin lesions were biopsied in 27 consenting patients with pSLE (≤16 years); however, due to technical difficulties, skin specimens of only 22 patients were available for immunohistochemistry. These included 15 (68.2%) patients who had lupus-specific lesions and 7 (31.8%) with lupus-nonspecific lesions. Immunohistochemical staining was done with the anti-interleukin-17 antibody (Genetix Biotech Asia Pvt. Ltd, New Delhi) [ Figure 1 ]. The expression of IL-17 was quantified independently by the primary investigator and the pathologist as the number of lymphocytes, fibroblasts and endothelial cells positive for IL-17 in 5 HPF and the average of the two readings was taken as the IL-17 count [ Figure 1 ]. The disease activity score SLEDAI-2K was calculated for each patient. The SLEDAI-2K score ranged from 2 to 27 and the mean SLEDIA-2K score was 13.63. IL-17 expression and SLEDAI-2K score were correlated using Spearman's rho correlation coefficient (R).
In our study, positive IL-17 expression in the inflammatory cells (lymphocytes, fibroblasts and endothelial cells) was appreciated in both lupus-specific and lupus-nonspecific lesions [ Table 1 ]. The mean IL-17 count of lupus-related lesions was 138 per 5 HPF (range: 24-400). The mean IL-17 count in lupus-nonspecific lesions and lupus-specific lesions was 146 and 134.2, respectively. The mean IL-17 count was higher in lesions of subacute LE (n = 3) than in acute cutaneous LE (n = 7) (P = 0.01) and chronic cutaneous LE (n = 5) (P < 0.01). This difference in the pattern of expression of IL-17 among the various lupus-specific lesions has not been previously reported.
There was no correlation between IL-17 expression in skin biopsies and the SLEDAI-2K score (R = −0.091). When analyzed separately, a negative correlation was seen in the case of lupus-specific lesions (R = −0.235) and a trend towards positive correlation was seen with regard to lupus-nonspecific lesions (R = 0.487).
Although serum IL-17 levels have been reported to correlate with the SLEDAI-2K score and cutaneous involvement in pSLE, [4] we did not observe a correlation between IL-17 expression in biopsies of lupus-related skin lesions and the SLEDAI-2K. There are no comparable studies in literature. No correlation was reported between IL-17 expression and Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI). [2] In addition, a recent study has reported a predominant role of interferon-γ (T H -1) than IL-17 (T H -17) axis in discoid lupus erythematosus. [5] The positive expression of IL-17 in skin lesions of SLE as seen in our study strengthens the emerging role of IL-17 in the pathogenesis of SLE and organ damage. [1] Further, there may be a role for IL-17 blockade in the management of recalcitrant cutaneous LE.
